Print This Page

 

February 19, 2015

China

Guolian Aquatic Products No Longer on FDA’s “Red List”

 

The USA Food and Drug Administration (FDA) removed Zhanjiang Guolian Aquatic Products Co., Ltd., from its “Red List” this month, putting an end to a period of big sales delays that cost the company millions of dollars.

 

Guolian—China’s largest shrimp exporter—had 170 containers of shrimp delayed by the earlier FDA ruling, resulting in $7,000 to $8,000 in fees per container for the FDA-mandated lab tests.  That equates to at least $1.2 million in added costs, but the time-consuming regulatory process was far more damaging to the company’s bottom line due to customers canceling orders and having to negotiate new prices.

 

According to the FDA, the “Red List”—more formally called “The Detention without Physical Examination (DWPE)”—flags companies that are found to have used unapproved antibiotics or chemicals.

 

“There is clear scientific evidence that the use of antibiotics or chemicals, such as malachite green, nitrofurans, fluoroquinolones, and gentian violet during the various stages of aquaculture can result in the presence of residues of the parent compound or its metabolites in the edible portion of the aquacultured seafood,” the FDA said in its February 11, 2015, alert, which effectively put Guolian back on its “Green List”.

 

Source: Undercurrent News [eight free news reads every month].  Editor, Tom Seaman (undercurrent@undercurrentnews.com).  FDA Antibiotics Crackdown Creates Big Losses for Guolian, Now Cleared.  Jeanine Stewart (jeanine.stewart@undercurrentnews.com).  February 18, 2015.

Print This Page